1

Principia

Oncology

www.principiabio.com

HBM contact: Dr Priyanka Belawat

Company status: public

A clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia's proprietary Tailored Covalency® platform enables them to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that they believe will rival those of injectable biologics, yet maintain the convenience of a pill.


© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171